These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37964501)

  • 1. Investigation of response of patients with non-small cell lung cancer to docetaxel (plus ramucirumab) therapy in second-line treatment.
    Takahara Y; Abe R; Nagae S; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
    Thorac Cancer; 2023 Dec; 14(36):3549-3555. PubMed ID: 37964501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
    Onoi K; Yamada T; Morimoto K; Kawachi H; Tsutsumi R; Takeda T; Okada A; Tamiya N; Chihara Y; Shiotsu S; Takemura Y; Yamada T; Hasegawa I; Katayama Y; Iwasaku M; Tokuda S; Takayama K
    Target Oncol; 2024 May; 19(3):411-421. PubMed ID: 38467958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.
    Garon EB; Visseren-Grul C; Rizzo MT; Puri T; Chenji S; Reck M
    Front Oncol; 2023; 13():1247879. PubMed ID: 37731641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.
    Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Yanagitani N; Horai T; Seike M; Gemma A; Nishio M
    Lung Cancer; 2020 Jun; 144():71-75. PubMed ID: 32387683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
    Garon EB; Scagliotti GV; Gautschi O; Reck M; Thomas M; Iglesias Docampo L; Kalofonos H; Kim JH; Gans S; Brustugun OT; Orlov SV; Cuyun Carter G; Zimmermann AH; Oton AB; Alexandris E; Lee P; Wolff K; Stefaniak VJ; Socinski MA; Pérol M
    ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer.
    Hamai K; Katsura R; Miyake S; Fujita S; Tada S; Hirakawa T; Ueno S; Tanimoto T; Ishikawa N
    Cancer Control; 2024; 31():10732748241274615. PubMed ID: 39120923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of using history of immune checkpoint inhibitor therapy for neutropenia caused by combination therapy of ramucirumab and docetaxel.
    Ohno H; Mano S; Katagiri N; Oguri R; Miyazaki K; Ito K; Sekiya Y; Inoue K; Masuda A; Tsuzuku A; Asano F; Hirashita T; Hayashi T
    Pharmazie; 2022 Sep; 77(7):248-254. PubMed ID: 36199179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
    Ishida M; Morimoto K; Yamada T; Shiotsu S; Chihara Y; Yamada T; Hiranuma O; Morimoto Y; Iwasaku M; Tokuda S; Takeda T; Takayama K
    Thorac Cancer; 2022 Jan; 13(2):173-181. PubMed ID: 34791812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
    Sakaguchi T; Furuya N; Ito K; Hida N; Morikawa K; Komase Y; Inoue T; Hataji O; Mineshita M
    Thorac Cancer; 2020 Jun; 11(6):1559-1565. PubMed ID: 32291896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
    Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
    Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
    Katayama Y; Yamada T; Sawada R; Kawachi H; Morimoto K; Watanabe S; Watanabe K; Takeda T; Chihara Y; Shiotsu S; Hibino M; Harada T; Nishioka N; Iwasaku M; Tokuda S; Takayama K
    Oncologist; 2024 May; 29(5):e681-e689. PubMed ID: 38241181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efforts to Reduce the Risk of Febrile Neutropenia and to Increase the Response Rate to Docetaxel and Ramucirumab Therapy in Patients with Non-Small Cell Lung Cancer].
    Yamamoto A; Iwata T
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1421-1425. PubMed ID: 31530782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
    Yamaguchi O; Mori K; Takata S; Shibata K; Chikamori K; Kimura N; Nagai Y; Nakagawa T; Igawa S; Harada T; Yoshioka H; Tanaka H; Nogawa H; Satoh H; Shiozawa T; Tsuji K; Kobayashi K; Kaira K
    Thorac Cancer; 2024 Jan; 15(2):163-171. PubMed ID: 38013668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial.
    Matsuzawa R; Morise M; Ito K; Hataji O; Takahashi K; Koyama J; Kuwatsuka Y; Goto Y; Imaizumi K; Itani H; Yamaguchi T; Zenke Y; Oki M; Ishii M
    EClinicalMedicine; 2023 Dec; 66():102303. PubMed ID: 38034077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.
    Kawachi H; Tamiya M; Matsumoto K; Tamiya A; Yanase T; Tanizaki S; Kumagai T
    Invest New Drugs; 2022 Jun; 40(3):634-642. PubMed ID: 35024985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.
    Tanizaki S; Matsumoto K; Tamiya A; Taniguchi Y; Matsuda Y; Uchida J; Ueno K; Kawachi H; Tamiya M; Yanase T; Suzuki H; Okishio K
    Eur J Clin Pharmacol; 2023 Apr; 79(4):503-511. PubMed ID: 36773042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
    Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
    Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
    Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.